







SCIENTIFIC PROGRAM page 1

UAE TIME	TOPIC	SPEAKER MODERATOR
8:30 - 9:00am	Registration	
9:00 - 9:05am	Opening	Prof. Humaid Al Shamsi
	HER-2 Positive	Dr. Aydah Al Awadhi Dr. Meteb Al-Foheidi
9:05 - 9:15am	Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52 / ATHENE)	Dr. Maroun El Khoury
9:15 - 9:25am	DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan vs treatment of physician's choice (TPC) in patients with human epidermal growth factor 2 (HER2)-low, estrogen-receptor expression immunohistochemistry 0-10% metastatic breast cancer	Dr. Aydah Al Awadhi
9:25 - 9:35am	Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)	Dr. Dima Abdul Jabbar
9:35 - 9:45am	HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies	Prof. Bassim Al Bahrani
9:45 - 9:55am	Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: a detailed safety analysis of the randomized, phase 3 DESTINY-breast04 trial	Dr. Bassel Jallad
9:55 - 10:15am	Panel Discussion	
10:15 - 10:30am	Risk of Recurrence in a Broader EBC HR+ HER2- patients: NATALEE updates	Dr. Fathi Azribi
	sponsored by NOVARTIS	moderated by Dr. Anwar Al Nouri
10:30 - 10:35am	COFFEE BREAK	
10:35 - 10:50am	Improving Survival and HR-QoL outcomes in HR+ HER2- Advanced Breast Cancer	
	sponsored by NOVARTIS	moderated by Dr. Anwar Al Nouri
	TNBC	Dr. Aydah Al Awadhi Dr. Anwar Al Nouri
10:50 - 11:00am	Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab plus chemotherapy followed by open-label adjuvant atezo in patients with early-stage triple-negative breast cancer	Dr. Saeed Rafii
11:00 - 11:10am	Homologous recombination status of platinum responsive advanced triple negative breast cancers treated with Olaparib +/- durvalumab maintenance therapy	Dr. Dalia Elshorbagy
11:10 - 11:20am	Circulating tumor DNA dynamics in patients receiving capecitabine for early-stage triple-negative breast cancer with an incomplete response to neoadjuvant therapy	Dr. Atlal Abusanad
11:20 - 11:35am	Panel Discussion	
11:35 - 12:05pm	Improving outcomes in early HER2+ breast cancer	Dr. Meteb Al-Foheidi
	sponsored by Pierre Fabre	
12:05 - 12:30am	Clinical Perspectives in Breast Cancer – Highlights from Chicago 2023	Dr. Hassan Ghazal












SCIENTIFIC PROGRAM page 2

UAE TIME	TOPIC	SPEAKER MODERATOR
	BC Surgery Session	Dr. Mona Al Ayyan Dr. Nahla Almansoori
12:30 - 12:40pm	De-escalating Surgery in Early Stage Breast Cancer	Dr. Rita Sakr
12:40 - 12:55pm	Panel Discussion	
12:55 - 01:20pm	Identification of HR+, HER2- Patients at High Risk of Recurrence in the Adjuvant setting or Progression in the metastatic setting	Dr. Aydah Al Awadhi
	sponsored by Lilly ONCOLOGY	
01:20 - 02:20pm	LUNCH BREAK	
	HR Positive	Dr. Falah Al Khatib Dr. Saeed Rafii
02:20 - 02:30pm	The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy - DATA trial analysis	Dr. Amin Abyad
02:30 - 02:40pm	Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2 -negative and triple negative breast cancer: results of part B of SOLTI TOT-HER3 window of opportunity trial (ID 137)	Dr. Diaeddine Trad
02:40 - 02:50pm	Capivasertib and fulvestrant for patients with aromatase inhibitor with aromatase inhibitor-resistant HR+/HER2- advanced breast cancer: subgroup analyses from the Phase 3 CAPItello-291 trial	Dr. Fathi Azribi
02:50 - 03:00pm	Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer	Dr. Aref Chehal
03:00 - 03:10pm	EMERALD trial analysis of patient-reported outcomes in patients with ER+/HER2-advanced or metastatic breast cancer comparing oral elacestrant vs standard of care endocrine therapy	Dr. Syed Hammad Tirmazy
03:10 - 03:40pm	ER+ HER- Advanced Breast Cancer: Clinical Advances in Endocrine Therapies	Dr. Aydah Al Awadhi
	sponsored by A Menarini Group Company	moderated by Dr. Saeed Rafii
03:40 - 03:50pm	Panel Discussion	
03:50 - 04:00pm	COFFEE BREAK	
	Tumor Board	Dr. Annett Al Hamadi Dr. Hassan Ghazal Dr. Ibrahim Abu-Gheida Dr. Mahmoud Abu Dakka
04:00 - 04:15pm	Case Presentation 1	Dr. Aydah Al Awadhi
04:15 - 04:40pm	Case Presentation 2	Dr. Saeed Rafii
04:30 - 04:45pm	Panel Discussion	
04:45 - 05:00pm	Closing Remarks & Appreciation Ceremony	Prof. Humaid Al Shamsi



managed by conveners





